Biomarkers in spondyloarthritis: From pathophysiology to disease assessment

Joint Bone Spine

Volumn 79, Issue 1, 2012, Pages 4-6

  Maksymowych, Walter P ^a  

^a UNIVERSITY OF ALBERTA   (Canada)

Author keywords

Ankylosing spondylitis; Biomarkers

Indexed keywords

ACUTE PHASE PROTEIN; ALKALINE PHOSPHATASE BONE ISOENZYME; BIOLOGICAL MARKER; C REACTIVE PROTEIN; CARBOXY TERMINAL TELOPEPTIDE; CARTILAGE OLIGOMERIC MATRIX PROTEIN; CD4 ANTIGEN; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; DICKKOPF 1 PROTEIN; INFLIXIMAB; INTERLEUKIN 17; INTERLEUKIN 2 RECEPTOR ALPHA; INTERLEUKIN 23; INTERLEUKIN 23 RECEPTOR; INTERLEUKIN 6; INTERLEUKIN 7; OSTEOCALCIN; OSTEOCLAST DIFFERENTIATION FACTOR; OSTEOPONTIN; OSTEOPROTEGERIN; SCLEROSTIN; SERUM AMYLOID A; STROMELYSIN; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR INHIBITOR; VASCULOTROPIN; WNT PROTEIN;

ANKYLOSING SPONDYLITIS; AS DISEASE ACTIVITY SCORE; BATH ANKYLOSING SPONDYLITIS DISEASE ACTIVITY INDEX; BONE DENSITY; BONE MATRIX; CD4+ T LYMPHOCYTE; DISEASE ACTIVITY; EDITORIAL; GENETIC POLYMORPHISM; HISTOPATHOLOGY; HUMAN; INFLAMMATION; OSSIFICATION; OSTEOBLAST; OSTEOCLAST; PATHOPHYSIOLOGY; PROGNOSIS; RATING SCALE; REGULATORY T LYMPHOCYTE; SCORING SYSTEM; SPONDYLARTHRITIS; TH17 CELL;

BIOLOGICAL MARKERS; C-REACTIVE PROTEIN; HUMANS; INFLAMMATION MEDIATORS; PROGNOSIS; SEVERITY OF ILLNESS INDEX; SPONDYLARTHRITIS;

EID: 84855715313     PISSN: 1297319X     EISSN: 17787254     Source Type: Journal    
DOI: 10.1016/j.jbspin.2011.09.018     Document Type: Editorial

References (20)

1. Poddubnyy D.A., Rudwaleit M., Listing J., et al. Comparison of a high sensitivity and standard C reactive protein measurement in patients with ankylosing spondylitis and non-radiographic axial spondyloarthritis. Ann Rheum Dis 2010, 69:1338-1341.
2. Visvanathan S., Wagner C., Marini J.C., et al. Inflammatory biomarkers, disease activity and spinal disease measures in patients with ankylosing spondylitis after treatment with infliximab. Ann Rheum Dis 2008, 67:511-517.
3. Wendling D., Cedoz J.P., Racadot E. Serum and synovial fluid levels of p40 IL12/23 in spondyloarthropathy patients. Clin Rheumatol 2009, 28:187-190.
4. Melis L., Vandooren B., Kruithof E., et al. Systemic levels of IL-23 are strongly associated with disease activity in rheumatoid arthritis but not spondyloarthritis. Ann Rheum Dis 2010, 69:618-623.
5. Rihl M., Kellner H., Kellner W., et al. Identification of interleukin-7 as a candidate disease mediator in spondylarthritis. Arthritis Rheum 2008, 58:3430-3435.
6. Pedersen S.J., Sorensen I.J., Garnero P., et al. ASDAS, BASDAI and different treatment responses and their relation to biomarkers of inflammation, cartilage and bone turnover in patients with axial spondyloarthritis treated with TNFalpha inhibitors. Ann Rheum Dis 2011, 70:1375-1381.
7. Choi S.T., Kim J.H., Kang E.J., et al. Osteopontin might be involved in bone remodelling rather than in inflammation in ankylosing spondylitis. Rheumatol 2008, 47:1775-1779.
8. Toussirot E., Saas P., Deschamps M., et al. Increased production of soluble CTLA-4 in patients with spondylarthropathies correlates with disease activity. Arthritis Res Ther 2009, 11:R101.
9. Chen C.H., Liao H.T., Chen H.A., et al. Soluble triggering receptor expressed on myeloid cell-1 (sTREM-1): a new mediator involved in early ankylosing spondylitis. J Rheumatol 2008, 35:1846-1848.
10. Maksymowych W.P., Rahman P., Shojania K., et al. Beneficial effects of Adalimumab on biomarkers reflecting structural damage in patients with ankylosing spondylitis. J Rheumatol 2008, 35:2030-2037.
11. Vandooren B., Kruithof E., Yu D.T., et al. Involvement of matrix metalloproteinases and their inhibitors in peripheral synovitis and down-regulation by tumor necrosis factor α blockade in spondylarthropathy. Arthritis Rheum 2004, 50:2942-2953.
12. Appel H., Janssen L., Listing J., et al. Serum levels of biomarkers of bone and cartilage destruction and new bone formation in different cohorts of patients with axial spondyloarthritis with and without tumor necrosis factor-alpha blocker treatment. Arthritis Res Ther 2008, 10:R125.
13. Maksymowych W.P., Poole A.R., Hiebert L., et al. Etanercept exerts beneficial effects on articular cartilage biomarkers of degradation and turnover in patients with ankylosing spondylitis. J Rheumatol 2005, 32:1911-1917.
14. Kim T.H., Stone M., Payne U., et al. Cartilage biomarkers in ankylosing spondylitis: relationship to clinical variables and treatment response. Arthritis Rheum 2005, 52:885-891.
15. Maksymowych W.P., Landewé R., Conner-Spady B., et al. Serum matrix metalloproteinase 3 is an independent predictor of structural damage progression in patients with ankylosing spondylitis. Arthritis Rheum 2007, 56:1846-1853.
16. Baraliakos X., Landewe R., van der Heijde D., et al. The relationship of biomarkers and radiographic progression in patients with ankylosing spondylitis treated with TNF-blockers. Ann Rheum Dis 2010, 69:105.
17. Baraliakos X., Landewe R., van der Heijde D., et al. A biomarker response is not associated with long-term radiographic progression in AS patients treated with infliximab: a follow-up evaluation of the ASSERT biomarker study. Ann Rheum Dis 2011, 70:343.
18. Diarra D., Stolina M., Polzer K., et al. Dickkopf-1 is a master regulator of joint remodeling. Nature Med 2007, 13:156-163.
19. Daoussis D., Liossis S.N., Solomou E.E., et al. Evidence that Dkk-1 is dysfunctional in ankylosing spondylitis. Arthritis Rheum 2010, 62:150-158.
20. Appel H., Ruiz-Heiland G., Listing J., et al. Altered skeletal expression of sclerostin and its link to radiographic progression in ankylosing spondylitis. Arthritis Rheum 2009, 60:3257-3262.